Sensitive serum parameters for hepatocellular carcinoma recurrence monitoring after liver transplantation: a case report.
Liver cell malignancy can be seen as one of the most common indications for hepatic transplantation, but the recurrence potential of the disease significantly limits its beneficial effects. Hepatic factors influencing the recurrence rate, such as nodule size and criteria wherein transplantations are expedited, are still investigated. Pretransplant intraarterial or percutaneous treatment seem to be predictive for recurrence-free patient survival. Early detection of malignancies via serum parameters as a prognostic factor seems promising. This article reports a special case, where despite an elevated, sensitive, serum marker profile, no HCC recurrence was detected over a 2-year follow-up.
Duller
D
D
Department of Transplantation, Medical University Graz, Gratz, Styria, Austria. dullerd@stud.meduni-graz.at
Stiegler
P
P
Schweiger
M
M
Kahn
J
J
Kniepeiss
D
D
Jakoby
E
E
Tscheliessnigg
K
K
Iberer
F
F
D001219:Aspartate Aminotransferases / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000601:surgery*; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000601:surgery; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000150:complications / Q000276:immunology / Q000601:surgery*; D016031:Liver Transplantation; D008875:Middle Aged; D012008:Recurrence; D012680:Sensitivity and Specificity; D000509:alpha-Fetoproteins / Q000032:analysis*
D014408:Biomarkers, Tumor; D007166:Immunosuppressive Agents; D000509:alpha-Fetoproteins; D001219:Aspartate Aminotransferases